US EditionBionova Scientific licenses ATUM’s proprietary transposon-based gene delivery technology - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Bionova Scientific licenses ATUM’s proprietary transposon-based gene delivery technology - Express Pharma
Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organisation (CDMO), announced it has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies. ATUM’s Leap-In Transposase technology can achieve high levels of gene integration, resulting in a large number of cells with the desired gene insertion, precise integration…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
